Re: The Effect of Restaging Transurethral Resection on Recurrence and Progression Rates in Patients with Nonmuscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10294513" target="_blank" >RIV/00216208:11130/15:10294513 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10294513

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.eururo.2014.12.050" target="_blank" >http://dx.doi.org/10.1016/j.eururo.2014.12.050</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.eururo.2014.12.050" target="_blank" >10.1016/j.eururo.2014.12.050</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Re: The Effect of Restaging Transurethral Resection on Recurrence and Progression Rates in Patients with Nonmuscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin

Popis výsledku v původním jazyce

The authors present a retrospective evaluation of data for 1021 patients treated between 1994 and 2006 with bacillus Calmette-Guerin (BCG) for high-risk non-muscle-invasive bladder cancer (NMIBC). They attempt to demonstrate the impact of a restaging/second transurethral resection of the bladder (2nd TURB) performed 2-6 wk after initial resection on treatment outcomes. The 2nd TURB before initiation of BCG therapy was performed in 894 patients, whereas 127 patients received BCG immediately after initialresection. All patients were treated with 6-weekly intravesical administration of Connaught strain BCG without maintenance therapy. After completion of the BCG regimen, patients were assessed regularly using office cystoscopy, cytology, and, if indicated, 2nd TURB.

Název v anglickém jazyce

Re: The Effect of Restaging Transurethral Resection on Recurrence and Progression Rates in Patients with Nonmuscle Invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin

Popis výsledku anglicky

The authors present a retrospective evaluation of data for 1021 patients treated between 1994 and 2006 with bacillus Calmette-Guerin (BCG) for high-risk non-muscle-invasive bladder cancer (NMIBC). They attempt to demonstrate the impact of a restaging/second transurethral resection of the bladder (2nd TURB) performed 2-6 wk after initial resection on treatment outcomes. The 2nd TURB before initiation of BCG therapy was performed in 894 patients, whereas 127 patients received BCG immediately after initialresection. All patients were treated with 6-weekly intravesical administration of Connaught strain BCG without maintenance therapy. After completion of the BCG regimen, patients were assessed regularly using office cystoscopy, cytology, and, if indicated, 2nd TURB.

Druh

O - Ostatní výsledky

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů